bioAffinity Technologies, Inc. — Director's Dealing 2024

Apr 24, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2024-04-08

Reporting Person: Zannes Maria (President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-08	Common Stock	M	64848	$1.16	Acquired	229506	Direct
2024-04-08	Common Stock	F	28264	$2.65	Disposed	201242	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-08	Stock Option (right to buy)	$1.16	M	64848	Disposed	2024-04-28	Common Stock (64848)	Direct

Footnotes

F1: Represents shares withheld to cover the exercise price of the options exercised.

F2: This option vested in 7 equal monthly installments beginning on April 28, 2014.